The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat

International Journal of Molecular Medicine

Volumn 25, Issue 6, 2010, Pages 875-882

  Matono, Tomomitsu ^a   Koda, Masahiko ^a   Tokunaga, Shiho ^a   Sugihara, Takaaki ^a   Ueki, Masaru ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Bile duct ligation; Eplerenone; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; EPLERENONE; MESSENGER RNA; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN K GROUP;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BLEEDING; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL;

ALDEHYDES; ANIMALS; BILE DUCTS; DEOXYGUANOSINE; GENE EXPRESSION REGULATION; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; LIGATION; LIPID PEROXIDATION; LIVER CIRRHOSIS; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SPIRONOLACTONE;

EID: 77952763556     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000417     Document Type: Article

References (31)

1. Oberti F, Rifflet H, Maiga MY, Pilette C, Gallois Y, Douay O, Jeune JJ, Saumet JL and Cales P: Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepaol 26: 167-173, 1997. (Pubitemid 27072618)
2. Oberti F, Pilette C, Rifflet H, Maiga MY, Moreau A, Gallois Y, Girault A, Bouil A, Jeune JJ, Saumet JL, Feldmann G and Cales P: Effects of simvastatin, pentxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepaol 26: 1363-1371, 1997. (Pubitemid 27346651)
3. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H: Angiotensin-II type 1 receptor interaction is a major regular for liver fibrosis development in rats. Hepatology 34: 745-750, 2001. (Pubitemid 32927999)
4. Struthers AD and MacDonald TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61: 663-670, 2004.
5. Fujisawa G, Muto S, Okada K, Kusano E and Ishibashi S: Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res 148: 149-156, 2006. (Pubitemid 44287632)
6. Ueki M, Koda M, Yamamoto S, Matsunaga Y and Murawaki Y: Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 41: 996-1004, 2006. (Pubitemid 44741413)
7. Remuzzi G, Cattaneo D and Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19: 1459-1462, 2008.
8. Ueki M, Koda M, Matono T, Sugihara T, Maeda K and Murawaki Y: Preventive and therapeutic effect of perindopril on hepatic fibrosis induced by bile duct ligation in rats. Mol Med Rep 2: 857-864, 2009.
9. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM and Powell EE: Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121: 148-155, 2001. (Pubitemid 32591525)
10. Caligiuri A, De Franco RM, Romanelli RG, Gentilini A, Meucci M, Failli P, Mazzetti L, Rombouts K, Geerts A, Vanasia M, Gentilini P, Marra F and Pizani M: Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gatoroenterology 124: 504-520, 2003. (Pubitemid 36169266)
11. Kurikawa N, Suga M, Kuroda S, Yamada K and Ishikawa H: An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 139: 1085-1094, 2003. (Pubitemid 36920670)
12. Kim MY, Baik SK, Park DH, Jang YO, Suk KT, Yea CJ, Lee IY, Kim JW, Kim HS, Kwon SO, Cho MY, Ko SB, Chang SJ, Um SH and Han KH: Angiotensin recetor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol 43: 889-896, 2008.
13. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y and Sakuta S: Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronichepatitis C. Hepatology 36: 1022, 2002.
14. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T,Tokusashi Y, Miyokawa N and Nakamura K: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40: 1222-1225, 2004. (Pubitemid 39425579)
15. Ueki M, Koda M, Shimizu T, Mitsuta A, Yamamoto T and Murawaki Y: Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology 56: 1100-1104, 2009.
16. White WB, Carr AA, Krause S, Jordan R, Roniker B and Oigman W: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92: 38-42, 2003. (Pubitemid 36782306)
17. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D and Saunders E: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41: 1148-1155, 2003. (Pubitemid 36384902)
18. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C and Lacolley P: Difference between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 7: 31-39, 2006. (Pubitemid 43891243)
19. Rastogi S, Mishra S, Zaca V, Alesh I, Gupta RC, Goldstein S and Sabbah HN: Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metlloproteinases in dogs with heart failure. Cardiovasc Drugs Ther 21: 415-422, 2007.
20. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, Hiroe M and Imanaka-Yoshida K: Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49: 261-268, 2007.
21. Lee BS, Kim NJ, Jeong HY, Lee HY, Kang DY and Noh SM: Change in serum cytokine concentration. A morphological study of liver cirrhosis induced by common bile duct ligation in rats. Korean J Intern Med 18: 6-12, 2003.
22. Akimoto T, Hayashi N, Adachi M, Kobayashi N, Zhang XJ, Ohsuga M and Katsuta Y: Viability and plasma vitamin K levels in the common bile duct-ligated rats. Exp Anim 54: 155-161, 2005.
23. Murawaki Y and Hirayama C: Hepatic collagenolytic cathepsin in patients with chronic liver disease. Clin Chim Acta 108: 121-128, 1980.
24. Wu LL, Chiou CC, Chang PY and Wu JT: Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chem Acta 339: 1-9, 2004.
25. Uchiyama M and Mihara M: Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271-278, 1978.
26. Toyokuni S: Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 49: 91-102, 1999.
27. Rombouts K, Niki T, Wielant A, Hellemans K, Schuppan D, Kormoss N and Geerts A: Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. J Hepatol 34: 230-238, 2001.
28. Alptekin N, Mehmetcik G, Uysal M and Aykac-toker G: Evidence for oxidative stress in the hepatic mitochondria of bile duct ligated rats. Pharmacol Res 36: 243-247, 1997.
29. Li X, Meng Y, Wu P, Zhang Z and Yang X: Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept 138: 15-25, 2007.
30. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K and Ogawa H: Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104: 137-139, 2001.
31. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Sumida H, Sugiyama S, Saito Y, Nakao K, Yasue H and Ogawa H: Aldosteron, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J 72: 1346-1350, 2008.